Page 2 - RP-AUGUST-2020

Osteoarthritis (OA) flare-up pain may not be under control1 Osteoarthritis (OA) flare-up pain may not be under control1 Osteoarthritis (OA) flare-up pain may not be under control1 Osteoarthritis (OA) flare-up pain may not be under control1 1 Nearly 3 in 5 (58.3%) patients with OA experienced pain in the last 4 weeks Nearly 3 in 5 (58.3%) patients with OA experienced pain in the last 4 weeks1 Nearly 3 in 5 (58.3%) patients with OA experienced pain in the last 4 weeks1 Nearly 3 in 5 (58.3%) patients with OA experienced pain in the last 4 weeks1 Almost half (48%) of patients with OA said their pain was bad enough to Almost half (48%) of patients with OA said their p1 ain was bad enough to interfere with their normal work in the last month Almost half (48%) of patients with OA said their pain was bad enough to interfere with their normal work in the last month1 Inflammation is a contributor to OA pain2 Inflammation is a contributor to OA pain2 Inflammation is a contributor to OA pain2 interfere with their normal work in the last month1 Almost half (48%) of patients with OA said their pain was bad enough to interfere with their normal work in the last month1 Inflammation is a contributor to OA pain2 OA pain is caused by inflammation within or around the joint.3 OA pain is caused by inflammation within or around the joint.3 4 Inflammation may result in redness, swelling, tenderness, and heat. OA pain is caused by inflammation within or around the joint.3 Inflammation may result in redness, swelling, tenderness, and heat.4 Inflammation may result in redness, swelling, tenderness, and heat.4 OA pain is caused by inflammation within or around the joint.3 Inflammation may result in redness, swelling, tenderness, and heat.4 An effective option for temporary relief of pain caused by inflammation are An effective option for temporary relief o5f pain caused by inflammation are anti-inflammatories, also called NSAIDs. An effective option for temporary relief of pain caused by inflammation are anti-inflammatories, also called NSAIDs.5 anti-inflammatories, also called NSAIDs.5 An effective option for temporary relief of pain caused by inflammation are Oral anti-inflammatories, such as Nurofen 400 Double Strength, are 5 aOnrtai-linafnlatim-imnfalatomrmieas,toarliseos,csaullcehdaNsSNAuIDrosf.en 400 Double Strength, are well-tolerated by the stomach when taken as directed, in patients with no Oral anti-inflammatories, such as Nurofen 400 Double Strength, are well-tolerated by the stomach when taken as directed, in patients with no contraindications or precautions (see pack label for contraindications and well-tolerated6–b8y the stomach when taken as directed, in patients with no Ocornatlraintdi-icnafltaiomnmsaotropriresc,asutciohnass(sNeeurpoafecnk4la0b0elDfourbcloenStrtareindgitcha,taiornesand precautions). What’s changed in your pharmacy? What’s changed in your pharmacy? What’s changed in your pharmacy? What’s changed in your pharmacy? 6–8 contraindications or precautions (see pack label for contraindications and wpreellc-atouletiroantse)d. by the stomach when taken as directed, in patients with no precautions).6–8 contraindications or precautions (see pack label for contraindications and Remember: OA symptoms and pain can change from day to day. Pain 6–8 pRreemcaeumtiboenrs:).OA symptoms and pain can change from day to day.3 Pain relievers are intended to reduce pain enough to allow movement. Remember: OA symptoms and pain can change from day to day. Pain relievers are intended to reduce pain enough to allow movement.3 relievers are intended to reduce pain enough to allow movement.3 Remember: OA symptoms and pain can change from day to day. Pain relievers are intended to reduce pain enough to allow movement.3 Modified-release paracetamol has been moved from Schedule 2 to Modified-release paracetamol has been moved from Schedule 2 to Schedule 3 (behind the counter). Refer patients to the pharmacist to Modified-release paracetamol has been moved from Schedule 2 to Schedule 3 (behind the counter). Refer patients to the pharmacist to discuss which treatment options will best suit them. Schedule 3 (behind the counter). Refer patients to the pharmacist to Mdioscduifsisedw-rheiclehatsreaptamreancet toapmtiolnhsaws ibllebeenstmsouvitetdhefrmo.m Schedule 2 to discuss which treatment options will best suit them. Schedule 3 (behind the counter). Refer patients to the pharmacist to This is an opportunity for many patients to receive a review of their pain dTihsicsuissawnhoicphpotrretauntmityenfot ropmtiaonys pwaitlilebnetsttosuriet ctheievme .a review of their pain management plan and make any necessary changes to optimise their This is an opportunity for many patients to receive a review of their pain management plan and make any necessary changes to optimise their treatment. management plan and make any necessary changes to optimise their Ttrheias tims eant.opportunity for many patients to receive a review of their pain treatment. management plan and make any necessary changes to optimise their treatment. For more information on the up-schedule For more information on the up-schedule scan the QR code THIS MEDICINE MAY NOT BE RIGHT FOR YOU. READ THE LABEL BEFORE PURCHASE. FOLLOW THE DIRECTIONS FOR USE. INCORRECT For more information on the up-schedule scan the QR code scan the QR code For more information on the up-schedule scan the QR code USE COULD BE HARMFUL. IF SYMPTOMS PERSIST, TALK TO YOUR HEALTHCARE PROFESSIONAL. ASK YOUR PHARMACIST – THEY THIS MEDICINE MAY NOT BE RIGHT FOR YOU. READ THE LABEL BEFORE PURCHASE. FOLLOW THE DIRECTIONS FOR USE. INCORRECT MUST DECIDE IF THIS PRODUCT IS RIGHT FOR YOU. FOR THE TEMPORARY RELIEF OF PAIN. USE COULD BE HARMFUL. IF SYMPTOMS PERSIST, TALK TO YOUR HEALTHCARE PROFESSIONAL. ASK YOUR PHARMACIST – THEY THIS MEDICINE MAY NOT BE RIGHT FOR YOU. READ THE LABEL BEFORE PURCHASE. FOLLOW THE DIRECTIONS FOR USE. INCORRECT MUST DECIDE IF THIS PRODUCT IS RIGHT FOR YOU. FOR THE TEMPORARY RELIEF OF PAIN. UNSEAICDOs: UnoLnD-stBerEoidHaAl aRnMti-FinUflaLm. ImFaStoYryMdPruTgOs.MOSA:PoEsRteSoaISrtTh,ritTisA. LK TO YOUR HEALTHCARE PROFESSIONAL. ASK YOUR PHARMACIST – THEY TMHUISTMDEEDCICIDINEEIFMTAHYISNPOROT BDEURCITGIHSTRFIGOHRTYFOUR. YROEAUD. FTOHERLTAHBEETLEBMEPFOREAPRUYRCEHLIAESFEO. FOPLALIONW. THE DIRECTIONS FOR USE. INCORRECT NSAIDs: non-steroidal anti-inflammatory drugs. OA: osteoarthritis. References: 1. Australian Institute of Health and Welfare 2019. Osteoarthritis. Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal- USE COULD BE HARMFUL. IF SYMPTOMS PERSIST, TALK TO YOUR HEALTHCARE PROFESSIONAL. ASK YOUR PHARMACIST – THEY conditions/osteoarthritis (accessed 29 April 2020). 2. Sokolove J and Lepus CM. Ther Adv Musculoskel Dis 2013;5(2):77–94. 3. Therapeutic Guidelines. MNRSeUAfSeIDTrseD:nEcoCenIs-Ds:teE1ro.IFiAdaTulHstarIanStli-aPinRflIOansmDtimtUuateCtoTorfyIHSderRuaglItGhs. HaOnTAdF:WOoseRtelfoaYareOrth2Ur0i.t1is9F..ORsteToHaErthTrEitMis.PAOvaRilAabRlYe fRroEmL:IEhFttpOs:F//PwAwIwN.a.ihw.gov.au/reports/chronic-musculoskeletal- Osteoarthritis. www.tgldcdp.tg.org.au. 4. Kielly J, et al. Can Pharm J (Ott) 2017;150(3):156 –168. 5. The Royal Australian College of General Practitioners. conditions/osteoarthritis (accessed 29 April 2020). 2. Sokolove J and Lepus CM. Ther Adv Musculoskel Dis 2013;5(2):77–94. 3. Therapeutic Guidelines. References: 1. Australian Institute of Health and Welfare 2019. Osteoarthritis. Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal- NOGSsuAtiedIoDealsir:ntenhorfiontir-ss.thewerowmiwda.ntlgalgdnectimd-ipne.nftlgat .omofmrkgna.aetoeur.ya4ndd.ruKhgiiesp.llyoOsJAt,e:eotoaasrtlhe.orCiatiarstn.h2rPinhtidsa.remdnJ.(EOatst)t M20e1lb7o;u1r5n0e(,3V):i1c:5R6A–C1G68P., 520.1Th8e.6R.oMyaoloAreusNtraeltianl.ColilnleDgreuogfIGnvenset r1a9l9P9r;a1c8ti:t8io9n–e9r8s. conditions/osteoarthritis (accessed 29 April 2020). 2. Sokolove J and Lepus CM. Ther Adv Musculoskel Dis 2013;5(2):77–94. 3. Therapeutic Guidelines. 7. Rampal P et al. J Int Med Res 2002;30:301–308. 8. Varrassi G et al. Adv Ther 2019; doi: 10.1007/s12325-019-01144-9. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, Vic: RACGP, 2018. 6. Moore N et al. Clin Drug Invest 1999;18:89–98. ROestfeoraernthcreitis.: w1w. Awu.tsgtrldaclidapn.tIgn.sotirtugt.eauo.f 4H.eaKlitehllaynJd, eWt aell.faCraen2P0h1a9.rmOsJte(Ooattr)th2r0it1is7.;A15va0i(l3a)b:l1e5f6ro–m1:6h8t.tp5s.:/T/hwewRwo.yailhAwu.gstorva.laiaun/rCeoplolergtse/cohfrGoneince-mraulsPcrualoctsiktieolneetarls-. 7. Rampal P et al. J Int Med Res 2002;30:301–308. 8. Varrassi G et al. Adv Ther 2019; doi: 10.1007/s12325-019-01144-9. cG®ounNidUietRilioOnneFsEf/oNorstithseeoaamrreatghnirsaitgeisreem(daectnrcatedossefemkdnae2rek9aoAfntdphrehiliRp2e0ock2sti0etto)B.ae2rnth.crkSiitosisek.ro2GlonrvdoeueJpdano.nf EdCaoLsemt pMpuaesnlbCieoMsu.r.LneTevh,eVlr4iAc7:,dR6vA8MC0GuGsPce,uo2lrog0se1k8eSl.t,6DS.iysMd2no0eo1yr3e2;0N50(2e0)t,:a7Nl7.S–CW9li4nA.Du3sr.turgTahliIenarv.aePpsrte1pu9ati9rce9Gd;1uJ8uid:l8ye92li–n09e28s0.. O7.stReaomarptharliPtise.twawl.wJ.ItngtlMdceddp.Rtges.o2rg0.0a2u;.340:.3K0i1el–ly30J,8e.t8a.l.VCaarrnasPshiaGrmetJa(lO.Att)dv20Th1e7r;125001(93;):d1o5i:61–01.6180.057/.sT1h2e3R2o5y-a0l1A9u-0st1ra1l4ia4n-9C.ollegeofGeneralPractitioners. ®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared July 2020. Guideline for the management of knee and hip osteoarthritis. 2nd edn. East Melbourne, Vic: RACGP, 2018. 6. Moore N et al. Clin Drug Invest 1999;18:89–98. ®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared July 2020. 7. Rampal P et al. J Int Med Res 2002;30:301–308. 8. Varrassi G et al. Adv Ther 2019; doi: 10.1007/s12325-019-01144-9. ®NUROFEN is a registered trademark of the Reckitt Benckiser Group of Companies. Level 47, 680 George St, Sydney 2000, NSW Australia. Prepared July 2020. An Update On The Treatment An Update On The Treatment An Update On The Treatment An Update On The Treatment Of OA Flare-up Pain Of OA Flare-up Pain Of OA Flare-up Pain Of OA Flare-up Pain